dexpramipexole
Small moleculeexperimental
Dexpramipexole (KNS-760704) is an orally administered drug candidate shown to selectively and significantly lower eosinophil counts in human blood and tissue. The drug is currently in clinical development for eosinophil-associated diseases by Knopp Biosciences LLC. — Wikipedia
Clinical trial activity
12 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01281189)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCCN[C@@H]1CCc2nc(N)sc2C1- Mol. weight
- 211.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL249420 ↗
- WikipediaDexpramipexole ↗
- ChEMBLCHEMBL2105687 ↗
Also known as
- dexpramipexole
- dexpramipexole
- dexpramipexole
- dexpramipexole
- dexpramipexole dihydrochloride
- dexpramipexole dihydrochloride
- dexprampexole
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04046939 | Phase 2 | Sep 1, 2019 | Knopp Biosciences |
| NCT02217332 | Phase 2 | Aug 1, 2014 | Knopp Biosciences |
| NCT02101138 | Phase 2 | Feb 20, 2014 | Knopp Biosciences, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01607034 | Phase 1 | Jun 1, 2012 | Knopp Biosciences |
| NCT01622088 | Phase 3 | Jun 1, 2012 | Biogen, Knopp Biosciences |
| NCT01597310 | Phase 1 | May 1, 2012 | Knopp Biosciences |
| NCT01536249 | Phase 1 | Mar 1, 2012 | Knopp Biosciences |
| NCT01511029 | Phase 1 | Jan 1, 2012 | Knopp Biosciences |
| NCT01449578 | Phase 1 | Nov 1, 2011 | Knopp Biosciences |
| NCT01424163 | Phase 1 | Aug 1, 2011 | Biogen, Knopp Biosciences |
| NCT01424176 | Phase 1 | Jul 1, 2011 | Knopp Biosciences |
| NCT01281189 | Phase 3 | Mar 1, 2011 | Knopp Biosciences |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Knopp Biosciences | For profit | 12 | 11 | 3 | 2011 |
| Biogen | For profit | 2 | 0 | 2 | 2011 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1